Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (odpre novo okno)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Vir‎: Hemoglobin 2014;38(1):44-8.

Indeksirano‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (odpre novo okno)

Hydroxyurea in thalassemia intermedia--a promising therapy. (odpre novo okno)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Vir‎: Ann Hematol 2005;84(7):441-6.

Indeksirano‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (odpre novo okno)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (odpre novo okno)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Vir‎: J Clin Pathol 2010;63(2):147-50.

Indeksirano‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (odpre novo okno)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (odpre novo okno)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Vir‎: Eur J Haematol 2009;82(3):213-8.

Indeksirano‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (odpre novo okno)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (odpre novo okno)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Vir‎: Eur J Haematol 2010;84(1):52-8.

Indeksirano‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (odpre novo okno)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (odpre novo okno)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Vir‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indeksirano‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (odpre novo okno)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (odpre novo okno)

Perrine SP.

Vir‎: Pediatr Ann 2008;37(5):339-46.

Indeksirano‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (odpre novo okno)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (odpre novo okno)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Vir‎: Ann N Y Acad Sci 2005;1054:250-6.

Indeksirano‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (odpre novo okno)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (odpre novo okno)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Vir‎: Acta Haematol 2004;111(4):189-95.

Indeksirano‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (odpre novo okno)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (odpre novo okno)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Vir‎: Blood Purif 2004;22(5):453-60.

Indeksirano‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (odpre novo okno)

The role of recombinant human erythropoietin in the treatment of thalassemia. (odpre novo okno)

Rachmilewitz EA, Aker M.

Vir‎: Ann N Y Acad Sci 1998;850:129-38.

Indeksirano‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (odpre novo okno)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (odpre novo okno)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Vir‎: Br J Haematol 2011;154(2):281-4.

Indeksirano‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (odpre novo okno)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (odpre novo okno)

Thein SL.

Vir‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indeksirano‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (odpre novo okno)